SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Peripheral Arterial Disease

In brief

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.

Key facts

Study ID
NCT02544204
Run by
Juventas Therapeutics, Inc.
People needed
120
Starts
2015-11-01
Expected to finish
2017-11-01
Last updated by the study team
2016-11-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.